Intas Pharmaceuticals Limited   Report issue

For profit Phase 1 Phase 3
Founded: Ahmedabad India (1984)
Status: No NME R&D (1984)

Organization Overview

First Clinical Trial
2018
NCT04014062
First Marketed Drug
2017
irinotecan (Camptosar)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Intas Pharmaceutical Limited (Biopharma Division) | Intas Pharmaceuticals Limited | Intas Pharmaceuticals, Ltd. | INTAS PHARMS LTD | INTAS PHARMS USA

Active Ingredients

Marketed Drugs (3)

irinotecan (Camptosar) (2017)

tipiracil (lonsurf) (2022)

trifluridine (viroptic) (2022)

Drugs in Phase 3 Trials (3)

denosumab (prolia) (1 trial)

docetaxel (taxotere) (1 trial)

endoxifen (1 trial)

Drugs in Phase 1 Trials (1)

Filgrastim (neupogen) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Disease (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4